Skip to main content
. 2015 Jan 16;6(6):3904–3917. doi: 10.18632/oncotarget.2880

Figure 1. The expression of MiR-23a in prostate cancer cell lines and tissues and its prognostic values in patients.

Figure 1

(A) MicroRNA expression profiling in prostate cancer were examined. 16 mRNAs with at least 10-fold expression down-regulated change were identified as altered markedly in prostate cancer (p < 0.05). (B) miR-23a expression were examined by real-time PCR in RWPE-1 cells and 5 prostate cancer cell lines (n = 3 replicate experiments; p < 0.05 compared with control). (C) miR-23a expression in 20 paired prostate cancer and adjacent non-tumour tissues. (D) miR-23a expression in ten primary and metastatic prostate cancer samples. (E) Kaplan-Meier analysis of survival times of patients with prostate cancer as a function of miR-23a levels.